Cancer, a type of horrifying disease indicated by the uncontrollable growth of abnormal cells into lumps called tumors (Peter Crosta, 2013). Tumors on the other hand can be classified into benign and malignant, depends on their harmfulness to the body. Several factors contribute to the incidence of cancer or increase the risk of getting cancer, these include mutations of DNA, hereditary factor, carcinogens and induced by other medications (Peter Crosta, 2013).
The incidence rate of cancers is increasing while the mortality rate of cancer patients is decreasing as we move on into a more advance era (Richard Manrow and Rebecca Chasan, 2013). People nowadays are exposing themselves to numerous kinds of carcinogens and radiation which they are not aware in this modern society. Less plant is available in the concrete city which is important in purifying the air we breathe and this leads to the increase risk of getting lung cancer. For the declining rate of mortality of cancer patients, it can be explained by the more sophisticated technology nowadays in treating cancer. This includes combination of chemotherapy, the approval of cancer prevention vaccines by the US FDA, therapies that target cancer cells at the molecular level, refined radiation therapy techniques and many more (Richard Manrow and Rebecca Chasan, 2013).
Although the mortality rate of cancer patients has shown to decline with more advancing technology, there is still a need to decrease the rate of developing cancer, increase the cure rate of cancer, and also to convert uncured cancer to a status of chronic disease (Richard Manrow and Rebecca Chasan, 2013). In order to produce an effective and potent anticancer drug, there are several criteria we have to look into. For instance, the role of metabolism, cell environment and also protein homeostasis should be taken into account in discovering anticancer drug.
To obtain the pharmacokinetic profile of an anticancer drug during the discovery process, metabolism plays a crucial role where the metabolic liability and the potential drug-drug interactions have to be determined (John Wiley and sons, 2001). Consequently, the metabolic stability of the drug has to be optimized and the drug-drug interactions should be minimized in order to produce an effective anticancer drug with minimum side effects (John Wiley and sons, 2001). Therefore, an accurate pharmacokinetic and metabolic data have to be obtained when the very first results of the in vitro biological screening are out (JiunnH.Lin et al, 1997). This aids in the early evaluations with quick information feedback which leads to gaining an optimal pharmacokinetic and pharmacological characteristics of the desired anticancer drug (JiunnH.Lin...